These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

187 related items for PubMed ID: 7354946

  • 21. [Controlled clinical trial of a new drug (plafibride) for the treatment of hyperlipoproteinemia type IV (author's transl)].
    Ferreira Montero IJ, Gutiérrez Martín M, del Río Ligorit A, Casasnovas Lenguas JA, Cornudella Lacasa R.
    Med Clin (Barc); 1982 May 01; 78(9):380-5. PubMed ID: 7047926
    [No Abstract] [Full Text] [Related]

  • 22. [Therapeutic experiences in the treatment of hyperlipoproteinaemia with etofylline clofibrate (author's transl)].
    Vorberg G, Ziegler WJ.
    Arzneimittelforschung; 1980 May 01; 30(11b):2068-72. PubMed ID: 7194062
    [Abstract] [Full Text] [Related]

  • 23. [Cross-over study of benfluorex and a hypolipemic agent in diet-resistant types IV and II b hyperlipemia (author's transl)].
    Graisely B, Cloarec M.
    Sem Hop; 1980 May 01; 56(25-28):1221-5. PubMed ID: 6256875
    [Abstract] [Full Text] [Related]

  • 24. Treatment of hyperlipoproteinemia, types II and IV, with pirifibrate: one hundred observations.
    Bonora V, Calalabuig RJ, Caviola E, Soler J, Pueyo JM, Micaló T, Cano RP.
    Clin Ther; 1981 May 01; 4(3):192-200. PubMed ID: 7030489
    [Abstract] [Full Text] [Related]

  • 25. [Etofibrate in severe diet-refractory cases of hyperlipoproteinemia].
    Schatton W, Holm E.
    Fortschr Med; 1986 Apr 03; 104(13):280-2. PubMed ID: 3699655
    [No Abstract] [Full Text] [Related]

  • 26. [Comparison of the lipid-lowering agents clofibrate and bezafibrate in patients with hyperlipoproteinemias IIa and IIb].
    Kokot F, Szczechowska E.
    Z Gesamte Inn Med; 1981 Jul 01; 36(13):454-7. PubMed ID: 7025475
    [Abstract] [Full Text] [Related]

  • 27. [Therapy of hyperlipoproteinemia type IIa, IIb and IV with Etofibrate retard].
    Schwartzkopff W, Schilling A, Calder D.
    Med Welt; 1980 Apr 04; 31(14):515-20. PubMed ID: 7374415
    [No Abstract] [Full Text] [Related]

  • 28. [Study of the antilipemic effect of etofibrate (Lipo-Merz)].
    Słowińska R, Bochenek W, Unlot J.
    Pol Tyg Lek; 1983 Apr 25; 38(17):529-32. PubMed ID: 6356087
    [No Abstract] [Full Text] [Related]

  • 29. [Atherosclerosis treatment with etofibrate retard. New perspectives].
    Degenring FH, Schatton W, Hotz W.
    Fortschr Med; 1983 Aug 11; 101(30):1391-6. PubMed ID: 6618402
    [Abstract] [Full Text] [Related]

  • 30. [Comparison of the hypolipemic effects of bezafibrate and fenofibrate in patients with hyperlipoproteinemia type II and IV].
    Sznajderman M.
    Przegl Lek; 1984 Aug 11; 41(7):493-9. PubMed ID: 6390536
    [No Abstract] [Full Text] [Related]

  • 31. Bioavailability studies of etofibrate in rhesus monkeys.
    Waller AR, Chasseaud LF, Taylor T, Schatton W.
    Arzneimittelforschung; 1985 Aug 11; 35(2):489-92. PubMed ID: 4039571
    [Abstract] [Full Text] [Related]

  • 32. [Lipid therapy with etofibrate. Reduction of multiple risk factors with an active substance. Report of an international seminar. 8-11 November 1989, Houston, Texas].
    Fortschr Med Suppl; 1990 Aug 11; 85():1-15. PubMed ID: 2338325
    [No Abstract] [Full Text] [Related]

  • 33. [Clinical effects and tolerance of etofylline clofibrate].
    Ziegler WJ, Metz G, Specker M.
    Arzneimittelforschung; 1980 Aug 11; 30(11b):2053-8. PubMed ID: 7194059
    [Abstract] [Full Text] [Related]

  • 34. Gemfibrozil--a new lipid lowering agent.
    Nash DT.
    J Med; 1980 Aug 11; 11(2-3):107-16. PubMed ID: 6931871
    [Abstract] [Full Text] [Related]

  • 35. [Effect of combination therapy of clofibric acid and nicotinic acid derivatives on fatty acid metabolism in hyperlipoproteinemia].
    Reuter W.
    Z Gesamte Inn Med; 1982 Oct 15; 37(20):682-8. PubMed ID: 6818779
    [Abstract] [Full Text] [Related]

  • 36. [Longterm therapy and etofibrate (author's transl)].
    Kaffarnik H, Schneider J, Schubotz R, Zöfel P.
    MMW Munch Med Wochenschr; 1980 Jan 18; 122(3):95-8. PubMed ID: 6767931
    [Abstract] [Full Text] [Related]

  • 37. [Lipid-lowering effect of etofibrate, bezafibrate and xanthinol nicotinate in patients with hyperlipoproteinemias].
    Machalke K, Djaja S, Richter E.
    Ther Ggw; 1982 May 18; 121(5):301-11. PubMed ID: 6953613
    [No Abstract] [Full Text] [Related]

  • 38. [The effect of bezafibrate on biliary lipids (author's transl)].
    Schlierf G, Fischer H, Roche A, Stiehl A, Oster P, Schellenberg B, Vollmar J.
    MMW Munch Med Wochenschr; 1980 Feb 01; 122(5):165-8. PubMed ID: 6767944
    [Abstract] [Full Text] [Related]

  • 39. Etofibrate decreases factor VII and fibrinogen levels in patients with polymetabolic syndrome.
    Jastrzebska M, Torbus-Lisiecka B, Pieczul-Mróz J, Chelstowski K, Kopciewicz J, Naruszewicz M.
    Int J Clin Pharmacol Res; 1999 Feb 01; 19(1):19-25. PubMed ID: 10450539
    [Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 10.